"All of these new findings correlate well together and highlight the prospects of EpCAM-directed immunotherapies," commented Carsten Reinhardt, M.D., Chief Medical Officer of Micromet. "While the findings from our collaborators in Munich may finally explain the well-known negative prognostic potential of EpCAM, the clinical data on adecatumumabs potential inhibitory effect on new metastases provide a clear rationale for moving forward into early-stage cancer settings where the goal is prevention of disease re- occurrence rather than palliative shrinkage of large tumor bulk."
All of the above cited abstracts can be viewed on the AACR website at http://www.aacr.org.
About Micromet, Inc. (http://www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the
development of novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases. Three of its antibodies are in
clinical development. MT103 (MEDI-538), the first antibody developed using
the BiTE(R) technology platform to be clinically validated in Micromet's
product pipeline, is being evaluated in a phase 1 clinical trial for the
treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies
represent a new class of antibodies that activate a patient's own cytotoxic
T cells to eliminate cancer cells. Micromet is developing MT103 in
collaboration with MedImmune, a subsidiary of AstraZeneca plc. The second
clinical stage antibody is adecatumumab (MT201), a human monoclonal
antibody targeting EpCAM expressing tumors. Adecatumumab is being developed
by Micromet in collaboration with Merck Serono, a division of Merck KGaA in
Darmstadt, Germany, in a phase 1b clinical trial evaluating MT201 in
combination with docetaxel for the treatment of patients with metastatic
breast cancer. The third clinical
|SOURCE Micromet, Inc.|
Copyright©2007 PR Newswire.
All rights reserved